vs
ZoomInfo Technologies Inc.（GTM）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
ZoomInfo Technologies Inc.的季度营收约是Orthofix Medical Inc.的1.5倍（$319.1M vs $219.9M），ZoomInfo Technologies Inc.净利率更高（10.9% vs -1.0%，领先11.9%），ZoomInfo Technologies Inc.同比增速更快（3.2% vs 2.0%），ZoomInfo Technologies Inc.自由现金流更多（$127.1M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 1.4%）
ZoomInfo Technologies Inc.是美国合规注册的数据服务商，通过数据采集、网页抓取等多元渠道汇总公开及非公开个人数据，同时收集企业、部门等商业主体信息，面向企业客户提供相关数据产品，助力客户开展精准营销等业务活动。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
GTM vs OFIX — 直观对比
营收规模更大
GTM
是对方的1.5倍
$219.9M
营收增速更快
GTM
高出1.3%
2.0%
净利率更高
GTM
高出11.9%
-1.0%
自由现金流更多
GTM
多$110.3M
$16.8M
两年增速更快
OFIX
近两年复合增速
1.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $319.1M | $219.9M |
| 净利润 | $34.7M | $-2.2M |
| 毛利率 | 84.0% | 71.1% |
| 营业利润率 | 17.0% | 0.2% |
| 净利率 | 10.9% | -1.0% |
| 营收同比 | 3.2% | 2.0% |
| 净利润同比 | 137.7% | 92.4% |
| 每股收益（稀释后） | $0.11 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GTMOFIX
| Q4 25 | $319.1M | $219.9M | ||
| Q3 25 | $318.0M | $205.6M | ||
| Q2 25 | $306.7M | $203.1M | ||
| Q1 25 | $305.7M | $193.6M | ||
| Q4 24 | $309.1M | $215.7M | ||
| Q3 24 | $303.6M | $196.6M | ||
| Q2 24 | $291.5M | $198.6M | ||
| Q1 24 | $310.1M | $188.6M |
净利润GTMOFIX
| Q4 25 | $34.7M | $-2.2M | ||
| Q3 25 | $38.7M | $-22.8M | ||
| Q2 25 | $24.0M | $-14.1M | ||
| Q1 25 | $26.8M | $-53.1M | ||
| Q4 24 | $14.6M | $-29.1M | ||
| Q3 24 | $23.8M | $-27.4M | ||
| Q2 24 | $-24.4M | $-33.4M | ||
| Q1 24 | $15.1M | $-36.0M |
毛利率GTMOFIX
| Q4 25 | 84.0% | 71.1% | ||
| Q3 25 | 83.7% | 72.2% | ||
| Q2 25 | 83.9% | 68.7% | ||
| Q1 25 | 84.5% | 62.8% | ||
| Q4 24 | 82.8% | 69.0% | ||
| Q3 24 | 84.4% | 68.7% | ||
| Q2 24 | 84.3% | 67.8% | ||
| Q1 24 | 86.0% | 67.5% |
营业利润率GTMOFIX
| Q4 25 | 17.0% | 0.2% | ||
| Q3 25 | 21.2% | -8.3% | ||
| Q2 25 | 17.5% | -7.9% | ||
| Q1 25 | 16.5% | -25.2% | ||
| Q4 24 | 10.0% | -5.3% | ||
| Q3 24 | 14.3% | -9.6% | ||
| Q2 24 | -6.9% | -12.5% | ||
| Q1 24 | 13.9% | -15.6% |
净利率GTMOFIX
| Q4 25 | 10.9% | -1.0% | ||
| Q3 25 | 12.2% | -11.1% | ||
| Q2 25 | 7.8% | -6.9% | ||
| Q1 25 | 8.8% | -27.4% | ||
| Q4 24 | 4.7% | -13.5% | ||
| Q3 24 | 7.8% | -13.9% | ||
| Q2 24 | -8.4% | -16.8% | ||
| Q1 24 | 4.9% | -19.1% |
每股收益（稀释后）GTMOFIX
| Q4 25 | $0.11 | $-0.05 | ||
| Q3 25 | $0.12 | $-0.57 | ||
| Q2 25 | $0.07 | $-0.36 | ||
| Q1 25 | $0.08 | $-1.35 | ||
| Q4 24 | $0.04 | $-0.76 | ||
| Q3 24 | $0.07 | $-0.71 | ||
| Q2 24 | $-0.07 | $-0.88 | ||
| Q1 24 | $0.04 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $179.9M | $82.0M |
| 总债务越低越好 | $1.3B | — |
| 股东权益账面价值 | $1.5B | $450.0M |
| 总资产 | $6.4B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.88× | — |
8季度趋势，按日历期对齐
现金及短期投资GTMOFIX
| Q4 25 | $179.9M | $82.0M | ||
| Q3 25 | $135.0M | $62.9M | ||
| Q2 25 | $176.9M | $65.6M | ||
| Q1 25 | $140.5M | $58.0M | ||
| Q4 24 | $139.9M | $83.2M | ||
| Q3 24 | $147.7M | $30.1M | ||
| Q2 24 | $399.3M | $26.4M | ||
| Q1 24 | $440.2M | $27.0M |
总债务GTMOFIX
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $157.2M | ||
| Q2 25 | $1.3B | $157.0M | ||
| Q1 25 | $1.2B | $156.9M | ||
| Q4 24 | $1.2B | $157.0M | ||
| Q3 24 | $1.2B | $118.5M | ||
| Q2 24 | $1.2B | $118.0M | ||
| Q1 24 | $1.2B | $118.2M |
股东权益GTMOFIX
| Q4 25 | $1.5B | $450.0M | ||
| Q3 25 | $1.5B | $442.5M | ||
| Q2 25 | $1.6B | $458.3M | ||
| Q1 25 | $1.6B | $458.3M | ||
| Q4 24 | $1.7B | $503.1M | ||
| Q3 24 | $1.7B | $525.9M | ||
| Q2 24 | $1.9B | $546.0M | ||
| Q1 24 | $2.0B | $570.3M |
总资产GTMOFIX
| Q4 25 | $6.4B | $850.6M | ||
| Q3 25 | $6.4B | $832.6M | ||
| Q2 25 | $6.5B | $837.2M | ||
| Q1 25 | $6.4B | $823.1M | ||
| Q4 24 | $6.5B | $893.3M | ||
| Q3 24 | $6.4B | $867.9M | ||
| Q2 24 | $6.7B | $882.0M | ||
| Q1 24 | $6.8B | $906.0M |
负债/权益比GTMOFIX
| Q4 25 | 0.88× | — | ||
| Q3 25 | 0.87× | 0.36× | ||
| Q2 25 | 0.85× | 0.34× | ||
| Q1 25 | 0.75× | 0.34× | ||
| Q4 24 | 0.72× | 0.31× | ||
| Q3 24 | 0.74× | 0.23× | ||
| Q2 24 | 0.66× | 0.22× | ||
| Q1 24 | 0.61× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $143.5M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $127.1M | $16.8M |
| 自由现金流率自由现金流/营收 | 39.8% | 7.6% |
| 资本支出强度资本支出/营收 | 5.1% | 4.9% |
| 现金转化率经营现金流/净利润 | 4.14× | — |
| 过去12个月自由现金流最近4个季度 | $389.3M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流GTMOFIX
| Q4 25 | $143.5M | $27.7M | ||
| Q3 25 | $93.8M | $12.4M | ||
| Q2 25 | $108.9M | $11.6M | ||
| Q1 25 | $119.2M | $-18.4M | ||
| Q4 24 | $109.0M | $23.7M | ||
| Q3 24 | $18.2M | $11.7M | ||
| Q2 24 | $126.3M | $9.0M | ||
| Q1 24 | $115.9M | $-18.6M |
自由现金流GTMOFIX
| Q4 25 | $127.1M | $16.8M | ||
| Q3 25 | $70.9M | $2.5M | ||
| Q2 25 | $86.9M | $4.5M | ||
| Q1 25 | $104.4M | $-25.1M | ||
| Q4 24 | $85.6M | $15.2M | ||
| Q3 24 | $600.0K | $6.3M | ||
| Q2 24 | $115.2M | $-360.0K | ||
| Q1 24 | $103.1M | $-29.1M |
自由现金流率GTMOFIX
| Q4 25 | 39.8% | 7.6% | ||
| Q3 25 | 22.3% | 1.2% | ||
| Q2 25 | 28.3% | 2.2% | ||
| Q1 25 | 34.2% | -13.0% | ||
| Q4 24 | 27.7% | 7.0% | ||
| Q3 24 | 0.2% | 3.2% | ||
| Q2 24 | 39.5% | -0.2% | ||
| Q1 24 | 33.2% | -15.4% |
资本支出强度GTMOFIX
| Q4 25 | 5.1% | 4.9% | ||
| Q3 25 | 7.2% | 4.8% | ||
| Q2 25 | 7.2% | 3.5% | ||
| Q1 25 | 4.8% | 3.5% | ||
| Q4 24 | 7.6% | 4.0% | ||
| Q3 24 | 5.8% | 2.7% | ||
| Q2 24 | 3.8% | 4.7% | ||
| Q1 24 | 4.1% | 5.6% |
现金转化率GTMOFIX
| Q4 25 | 4.14× | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 4.45× | — | ||
| Q4 24 | 7.47× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 7.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTM
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
